<DOC>
	<DOC>NCT01290211</DOC>
	<brief_summary>This is will be an open-label, fixed-sequence, multiple dose crossover study in 2 cohorts of 14 healthy male and/or female subjects, to estimate the effect of maraviroc on the pharmacokinetics of amprenavir and ritonavir and fosamprenavir/ritonavir on the pharmacokinetics of maraviroc.</brief_summary>
	<brief_title>Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2. Total body weight &gt;50 kg (110 lbs). History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening. Positive result for HIV, Hepatitis B or Hepatitis C virus. Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 halflives preceding the first dose of study medication. Known hypersensitivity or history of allergy to sulfonamides.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>maraviroc</keyword>
	<keyword>fosamprenavir</keyword>
	<keyword>drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>CCR5</keyword>
	<keyword>protease inhibitor</keyword>
</DOC>